FAQs Sign up for updates

Want to know the latest on AUM's products?

Sign up today to get the most exclusive discounts offers

Why Use AUMsilence Oligos for RNA Silencing?

AUMsilence ASOs vs. siRNAs
The basics
Not Required Transfection Reagents Required
AUMsilence oligo technology allows very high specificity for the target RNA Specificity siRNA grade specificity
None RISC associated Off target effects Yes
Easy and convenient single step process Transition from basic cell lines to primary cells to animal models Require extensive optimization and use of delivery reagents
Ease of use in different model systems
Easy to use. No transfection reagents required. Mix AUMsilence oligos with the cells Basic Cell lines Need transfection reagents. Transfection reagent based optimization required
Easy to use. No transfection reagents required. Mix AUMsilence ASO oligos with the cells Primary cells and difficult to transfect cells Need transfection reagents that kills the sensitive cells and sometimes alter the biology
Can work in fish models (example zebrafish) Fish models Not recommended for fish models
Key Attributes
Non-toxic Toxicity Can be toxic
Resistant to degradation by serum and cellular nucleases Stability Moderate stability
Minimal resources needed and easy to optimize Resources and time saving Require additional reagents and machines. Time consuming optimization
Up to 80% more cost effective in terms of time and money. Cost saving Expensive to use

Comparison of AUMsilence ASO and siRNA mode of action

As opposed to the RNAi pathway (involving RISC) AUMsilence single-stranded antisense oligonucleotides use RNase H-mediated cleavage. This mode of mRNA knockdown is simpler than siRNA mediated knockdown and eliminates RISC-associated off-target effects often observed with siRNA. Unlike siRNAs that are processed in the cytoplasm, AUMsilence oligos can go into the nucleus and can be used to target RNA present within the nucleus. Most importantly AUMsilence oligos can be self delivered and do not need transfection reagents or delivery agents.

Comments on AUMsilence ASO Technology

Publications on AUMsilence oligos

Publications from 2019

Karyn Schmidt, Johanna S. Carroll, Elaine Yee, Dolly D. Thomas, Leon Wert-Lamas, Steven C. Neier, Gloria Sheynkman, Justin Ritz, Carl D. Novina. The lncRNA SLNCR Recruits the Androgen Receptor to EGR1-Bound Genes in Melanoma and Inhibits Expression of Tumor Suppressor p21, Cell Reports, Volume 27, Issue 8,2019, 2493-2507.e4, SSN 2211-1247, https://doi.org/10.1016/j.celrep.2019.04.101

View Publication
Publications from 2019

Mayumi Takahashi, Haitang Li, Jiehua Zhou, Pritsana Chomchan, Veenu Aishwarya, Masad J. Damha, John J. Rossi, Dual mechanisms of action of self-delivering, anti-HIV-1 FANA oligonucleotides as a potential new approach to HIV therapy, Molecular Therapy - Nucleic Acids, 2019.https://doi.org/10.1016/j.omtn.2019.07.001

View Publication
Publications from 2019

Suwanmanee, S., Mahakhunkijcharoen, Y., Ampawong, S., Leaungwutiwong, P., Missé, D., Luplertlop, N. (2019). Inhibition of N‐myristoyltransferase1 affects dengue virus replication. MicrobiologyOpen; e831. https://doi.org/10.1002/mbo3.831

View Publication
Publications from 2018

Chorzalska, A., Morgan, J., Ahsan, N., Treaba, D. O., Olszewski, A. J., Petersen, M., … Dubielecka, P. M. (2018). Bone marrow-specific loss of ABI1induces myeloproliferative neoplasm with features resembling human myelofibrosis. Blood, 132(19), 2053–2066. doi:10.1182/blood-2018-05-848408

View Publication
Publications from 2018

Frank, S., Ahuja, G., Bartsch, D., Russ, N., Yao, W., Kuo, J. C. C., ... & Messling, J. E. (2018). yylncT Defines a Class of Divergently Transcribed lncRNAs and Safeguards the T-mediated Mesodermal Commitment of Human PSCs. Cell stem cell, 24(2), 318-327. doi:10.1016/j.stem.2018.11.005.

View Publication
Publications from 2018

Ludlow, A. T., Wong, M. S., Robin, J. D., Batten, K., Yuan, L., Lai, T. P., … Shay, J. W. (2018). NOVA1 regulates hTERT splicing and cell growth in non-small cell lung cancer. Nature communications. Nature Communications, 9(1), 3112. doi:10.1038/s41467-018-05582-x

View Publication

Award Winning Technology

We would like to congratulate Dr. Mayumi Takahashi, Beckman Research Institute of City of Hope, California on receiving the Dr. Alan M. Gewirtz Memorial Scholarship. This award is given to outstanding scientists and recognizes their contributions in the field of oligonucleotide therapeutics. In her work, Dr. Takahashi used ASOs to inhibit HIV-1 replication with a goal to develop ASO based therapeutics for HIV.


Much more convenient than siRNA, shRNA or CRISPR

in vitro

No Transfection Reagents Needed (Self-Delivery Or Gymnosis)

We take pride in having the simplest protocol for RNA silencing studies. AUMsilence oligos can work with any cell type without causing toxicity. AUMsilence oligos can work with easy to transfect, hard to transfect (like primary cells, b-cells, t-cells, neurons etc.) and highly sensitive patient samples.


in vivo

No Delivery Vehicle, Formulations Or Conjugates Needed

It is recommended to test a few doses of AUMsilence oligos. Recommended dose is between 3 – 30 mg/kg in mice. Administration routes: Depending upon your experimental purpose you may choose from Subcutaneous, Intrathecal, Oral or Intestinal.


About us

AUM BioTech is a Philadelphia based biotechnology company with a revolutionary nucleic acids platform in the gene silencing and regulation space. AUM’s AUMsilence ASO RNA silencing and regulation technology can be used to very efficiently target a variety of RNA modalities like – mRNA, microRNA and long non-coding RNA. AUMsilence ASO technology can be used for discovery, translational and potentially for therapeutic development. Considering the versatility of our next generation RNA silencing and regulation platform AUM is now making the AUMsilence ASO technology available to biomedical researchers across the globe.